Biography
Dr. Jaideep Singh is currently a postdoctoral researcher at the Heart Research Institute (HRI), Sydney, Australia. Prior to joining HRI, he was a research fellow at Monash University, Australia. Dr. Singh completed his PhD at the Baker Heart and Diabetic Institute and Monash University in 2024. During his doctoral studies, Dr. Singh discovered Cmpd17b as a novel treatment for hypertension-induced heart failure and aortic aneurysm and elucidated the mechanisms underlying its therapeutic effects. This significant work has been featured in various media outlets, including the Herald Sun newspaper. Before starting his PhD, Dr. Singh amassed 11 years of experience in leading research and development companies, including Zydus, Syngene International, and Connexios Life Sciences in India.
Dr Singh has made key contributions to the development of new drug candidates targeting metabolic, autoimmune, and cardiovascular disorders. His innovative approach of repurposing existing drugs for autoimmune diseases led to four patent filings aimed at developing affordable treatments to improve patient care. He has generated outstanding research, with 19 articles published in prestigious journals, including Cardiovascular Research and Communications Biology (Nature Portfolio). He has also presented his work at numerous national and international conferences and has received eight prestigious awards, including the International Society of Heart Research Investigator Prize, the Ralph Reader Award, and an Emerging Researcher Award in industry.
In 2024, he was awarded the Glenys Fitzpatrick Fellowship to support his postdoctoral research at HRI.
Patents
Co-inventor, WO2019/142124A1, Pharmaceutical compositions for treatment of vitiligo.
Co-inventor, US20200179339, Pharmaceutical compositions for treatment of atopic dermatitis.
Co-inventor, IN201921046094, Pharmaceutical compositions for treatment of vitiligo.
Co-inventor, IN202021007941A, Pharmaceutical compositions for treatment of alopecia.
Publications
Singh J, Jackson KL, Fang H, Gumanti A, Claridge B, Tang FS, Kiriazis H, Salimova E, Parker AM, Nowell CJ, Woodman OL, Greening DW, Ritchie RH, Head GA, Qin CX. The Novel formylpeptide receptor 1/2 agonist limits hypertension-induced cardiovascular damage. Cardiovascular Research, 2024; 120(11): 1336-1350.
Singh J, Jackson KL, Tang FS, Fu T, Nowell C, Salimova E, Kiriazis H, Ritchie RH, Head GA, Woodman OL, Qin CX. The pro-resolving mediator, annexin A1 regulates blood pressure, and age-associated changes in cardiovascular function and remodeling. Federation of American Societies for Experimental Biology, 2024; 38(3): e23457.
Jelinic M, Jackson KL, O'Sullivan K, Singh J, Giddy T, Deo M, Parry LJ, Ritchie RH, Woodman OL, Head GA, Leo CH, Qin CX. Endothelium-dependent relaxation is impaired in Schlager hypertensive (BPH/2J) mice by region-specific mechanisms in conductance and resistance arteries. Life sciences, 2023; 320: 121542.
Ghoshdastidar K, Patel H, Bhayani H, Patel A, Thakkar K, Patel D, Sharma M, Singh J, Mohapatra J, Chatterjee A. ZYBT1, a potent irreversible Bruton’s tyrosine kinase (BTK) inhibitor that inhibits C481S BTK with profound efficacy against arthritis and cancer. Pharmacology Research & Perspectives, 2020; 8(4): e00565.
Giri P, Delvadia P, Gupta L, Trivedi P, Singh J, Chatterjee A, Srinivas NR. Impact of collagen induced arthritis on the pharmacokinetic disposition of voriconazole, a widely used antifungal agent: in vitro and in vivo investigations in DBA/1J mice. Xenobiotica, 2019; 49(6): 698-707.
Sunil V, Verma MK, Oommen AM, Sadasivuni M, Singh J, Vijayraghav DN, Chandravanshi B, Shetty J, Biswas S, Dandu A, Moolemath Y, Venkataranganna MV, Somesh BP, Jagannath MR. CNX-011-67, a novel GPR40 agonist, enhances glucose responsiveness, insulin secretion and islet insulin content in n-STZ rats and in islets from type 2 diabetic patients. BMC Pharmacology and Toxicology, 2014; 15: 19.
Anil TM, Dandu A, Harsha K, Singh J, Shree N, Kumar VS, Lakshmi MN, Sunil V, Harish C, Balamurali GV, Naveen Kumar BS, Gopala AS, Pratibha S, Sadasivuni M, Anup MO, Moolemath Y, Venkataranganna MV, Jagannath MR, Somesh BP. A novel 11β-hydroxysteroid dehydrogenase type1 inhibitor CNX-010-49 improves hyperglycemia, lipid profile and reduces body weight in diet induced obese C57B6/J mice with a potential to provide cardio protective benefits. BMC Pharmacology and Toxicology, 2014; 15: 43.
Sadasivuni MK, Reddy BM, Singh J, Anup MO, Sunil V, Lakshmi MN, Yogeshwari S, Chacko SK, Pooja TL, Dandu A, Harish C, Gopala AS, Pratibha S, Naveenkumar BS, Pallavi PM, Verma MK, Moolemath Y, Somesh BP, Venkataranganna MV, Jagannath MR. CNX-013-B2, a unique pan tissue acting rexinoid, modulates several nuclear receptors and controls multiple risk factors of the metabolic syndrome without risk of hypertriglyceridemia, hepatomegaly and body weight gain in animal models. Diabetology & Metabolic Syndrome, 2014; 6: 83.
Sadasivan SK, Vasamsetti B, Singh J, Siddaraju N, Khan KM, Oommen AM, Jagannath MR, Rao RP. Modulation of de novo purine biosynthesis leads to activation of AMPK and results in improved glucose handling and insulin sensitivity. Journal of Diabetes & Metabolic Disorders, 2014; 13: 51.
Sadasivan SK, Vasamsetti B, Singh J, Marikunte VV, Oommen AM, Jagannath MR, Pralhada Rao R. Exogenous administration of spermine improves glucose utilization and decreases bodyweight in mice. European Journal of Pharmacology, 2014; 729: 94-99.
Gowda N, Dandu A, Singh J, Biswas S, Raghav V, Lakshmi MN, Shilpa PC, Sunil V, Reddy A, Sadasivuni M, Aparna K, Verma MK, Moolemath Y, Anup MO, Venkataranganna MV, Somesh BP, Jagannath MR. Treatment with CNX-011-67, a novel GPR40 agonist, delays onset and progression of diabetes and improves beta cell preservation and function in male ZDF rats. BMC Pharmacology and Toxicology, 2013; 14: 28.
Singh J, Samir C. Pharmacokinetic changes of Fluvoxamine and Pioglitazone by drug interaction in healthy, diabetic, and depressive rats. International Journal of Pharmacy and Pharmaceutical Sciences, 2013; 5(1): 352-355.
Singh J, Samir C. Influence of Esomeprazole on the pharmacokinetic and pharmacodynamic properties of glipizide in normal and diabetic guinea pigs. Indo American Journal of Pharmaceutical Research, 2012; 2: 10.
Banji D, Singh J, Banji OJ, Shanthamurthy M. Scrutinizing the aqueous extract of leaves of Pedalium murex for the antiulcer activity in rats. Pakistan Journal of Pharmaceutical Sciences, 2010; 23(3): 295-299.
Babitha S, Ramesh B, Singh J. A study on drug-drug interaction of Pantoprazole with Glipizide in rabbits. Pharmacologyonline, 2009; 2: 667-672.
Media/Press
Awards and Recognitions
2025 Glenys Fitzpatrick Fellowship, Australia
2024 Ralph Reader prize winner at CSANZ Scientific Meeting, Australia
2023 Best Oral Presentation winner at ASCEPT CVSIG Symposium, Australia
2023 Poster presentation finalist at the World Congress of Pharmacology, United Kingdom
2022 Early Career Investigator Excellence 2022 Award, Australia
2022 ISHR Student Investigator Award at CSANZ Scientific Meeting, Australia
2022 Best Oral Presentation winner at AIM Symposium, Australia
2022 Best Oral Presentation winner at ASMR Symposium, Australia
2020 Monash Graduate Scholarship, Australia
2019 Emerging Researcher Award, Zydus Lifesciences, India
2008 All India Council for Technical Education Master’s Research Scholarship, India